SCHEMBL434414

SCHEMBL434414

O=C(O)CCCCBr.c1ccc(P(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 2/20 0.52
HDAC4 P56524 2/20 0.52
HDAC1 Q13547 2/20 0.52
HDAC7 Q8WUI4 2/20 0.52
HDAC2 Q92769 2/20 0.52
HDAC10 Q969S8 2/20 0.52
HDAC11 Q96DB2 2/20 0.52
HDAC8 Q9BY41 2/20 0.52
HDAC6 Q9UBN7 2/20 0.52
HDAC9 Q9UKV0 2/20 0.52
HDAC5 Q9UQL6 2/20 0.52
MAPT P10636 2/20 0.47
RXFP1 Q9HBX9 1/20 0.47
MAPK1 P28482 2/20 0.46
ADRA1A P35348 1/20 0.46
SLC6A3 Q01959 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
FABP4 P15090 2/20 0.45
FABP5 Q01469 2/20 0.45
TDP1 Q9NUW8 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11794783 0.98 HDAC3 (0.55) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL7619905 0.98 HDAC3 (0.55) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL9665256 0.98 HDAC3 (0.55) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL9578909 0.98 HDAC3 (0.55) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL10472224 0.98 HDAC3 (0.55) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL2443584 0.94 HDAC3 (0.47) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL435538 0.86 CYP3A4 (0.50) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL25222408 0.84 HDAC3 (0.47) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL5453551 0.84 TDP1 (0.63) MAPTTDP1CYP3A4L3MBTL1LMNA
Succinic Acid SCHEMBL7629002 0.82 CYP3A4 (0.60) HDAC3HDAC4HDAC1HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115340571-B Preparation method and application of novel artemisinin derivative and liposome 中国中医科学院中药研究所 2024-09-27 CN claimed
US-20130184476-A1 PREPARATION OF LUBIPROSTONE DR. REDDY'S LABORATORIES LTD. (IN) 2013-07-18 US claimed
JP-58124791-A None JP disclosed
CN-115340571-B Preparation method and application of novel artemisinin derivative and liposome 中国中医科学院中药研究所 2024-09-27 CN disclosed
CN-118679165-A Photodynamic therapy and diagnosis RMW曹氏集团有限公司 2024-09-20 CN disclosed
CN-118010865-A HPLC detection method for homologs in 4-carboxybutyltriphenylphosphine bromide 时森海(杭州)医药科技有限公司 2024-05-10 CN disclosed
CN-118019801-A Fluoropolymer compositions and methods of making the same 阿科玛股份有限公司 2024-05-10 CN disclosed
CN-117843599-A Preparation method of prostaglandin intermediate containing 1-alkyl-1-alkenyl ethanol structure 广州楷石医药有限公司 2024-04-09 CN disclosed
CN-115337297-B CPI-613 mitochondrial targeting small molecule prodrug, self-assembled nanoparticle thereof, preparation method and application 沈阳药科大学 2024-01-30 CN disclosed
CN-115160202-B Preparation method of carboprost tromethamine and intermediate thereof 广州楷石医药有限公司 2023-10-31 CN disclosed
CN-116615251-A Antibody-drug conjugates comprising GLP1 peptide mimetics and the uses thereof 瑞泽恩制药公司 2023-08-18 CN disclosed
US-4035392-A Prostanoic acid intermediate CARLO ERBA S.P.A. (IT) 1977-07-12 US disclosed
US-4035414-A Prostanoic acid derivatives CARLO ERBA S.P.A. (IT) 1977-07-12 US disclosed
US-4021477-A 14-Chloro prostadienoic acid compounds CARLO-ERBA S.P.A. (IT) 1977-05-03 US disclosed
US-3987087-A ANTI-ULCER, NASAL PATENCY, WOUND HEALING, LABOR INDUCEMENT THE UPJOHN COMPANY (US) 1976-10-19 US disclosed
US-3987085-A PROSTAGLANDINS THE UPJOHN COMPANY (US) 1976-10-19 US disclosed
US-3975404-A Bicyclic lactone intermediates THE UPJOHN COMPANY (US) 1976-08-17 US disclosed
US-3969396-A 8β, 11β, 12α-PGE2 compounds THE UPJOHN COMPANY (US) 1976-07-13 US disclosed
US-3954833-A PROSTAGLANDINS THE UPJOHN COMPANY (US) 1976-05-04 US disclosed
US-3935254-A 5C-PROSTEN-13-YNOIC ACIDS CARLO ERBA S.P.A. (IT) 1976-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130184476-A1 PREPARATION OF LUBIPROSTONE PTGIR, PTGIS, VASP HDAC3 3014/4885HDAC4 2586/4885HDAC1 3763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.